Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01939275 · ClinicalTrials.gov registry record · NA
64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer
A NA study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT01939275 is a NA study that has completed, run by City of Hope Medical Center. The registered enrollment target is 8 participants.
The verdict
NCT01939275, a NA study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
This pilot clinical trial studies copper Cu 64 (64Cu) tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET)/computed tomography (CT) in studying patients with gastric, or stomach cancer. Diagnostic procedures, such as copper Cu 64-DOTA-trastuzumab PET/CT, may help doctors study the characteristics of tumors and choose the best treatment.
Interventions
- PROCEDURE Computed Tomography
- OTHER laboratory biomarker analysis
- RADIATION copper Cu 64-DOTA-trastuzumab
- DEVICE positron emission tomography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-11-19 |
| Est. Completion | 2024-08-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01939275
The ClinicalTrials.gov registry entry for NCT01939275 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Computed Tomography is the first listed.
NCT01939275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01939275 about?
NCT01939275 is a clinical study titled "64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer". This pilot clinical trial studies copper Cu 64 (64Cu) tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET)/computed tomography (CT) in studying patients with gastric, or stomach cancer. Diagnostic procedures, such as copper Cu 64-DOTA-trastuzumab PET/CT, may ...
What is the current status of trial NCT01939275?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2014-11-19. Estimated completion is 2024-08-05.
What interventions are being tested in trial NCT01939275?
The interventions under investigation include: Computed Tomography (PROCEDURE), laboratory biomarker analysis (OTHER), copper Cu 64-DOTA-trastuzumab (RADIATION), positron emission tomography (DEVICE).
Who is sponsoring clinical trial NCT01939275?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.